Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas-ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2023

  1. Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial function

    Molecular Metabolism, Vol. 75

  2. Neddylation of phosphoenolpyruvate carboxykinase 1 controls glucose metabolism

    Cell Metabolism, Vol. 35, Núm. 9, pp. 1630-1645.e5

2022

  1. Cardiometabolic characterization in metabolic dysfunction–associated fatty liver disease

    Frontiers in Medicine, Vol. 9

  2. Transient elastography and serum markers of liver fibrosis associate with epicardial adipose tissue and coronary artery calcium in NAFLD

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. O-GlcNAcylated p53 in the liver modulates hepatic glucose production

    Nature Communications, Vol. 12, Núm. 1

  3. Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points

    Journal of Hepatology

2020

  1. Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD

    FASEB Journal, Vol. 34, Núm. 9, pp. 11816-11837

2016

  1. Factors related to increased resting energy expenditure in men with liver cirrhosis

    European Journal of Gastroenterology and Hepatology, Vol. 28, Núm. 2, pp. 139-145